News Headlines Article

CMS holds off on CAR-T cancer treatment coverage decision
Modern Healthcare

The CMS on Friday postponed its decision on whether to cover a pricey, breakthrough cancer treatment.

Although Friday marked the agency’s deadline for its national coverage determination decision, the CMS did not elaborate on why it decided to hold off. Chimeric antigen receptor T-cell therapy, or CAR-T, is an immunotherapy cancer treatment.

The agency did not immediately respond to a request for comment, but said in the announcement that a decision would be forthcoming.